Seres Therapeutics, Inc. Stock Issued During Period, Shares, New Issues
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Seres Therapeutics, Inc. stock issued during period, shares, new issues for the quarter ending 2025-12-31 was 0.00 shares, a 100.00% decline year-over-year.
- Seres Therapeutics, Inc. stock issued during period, shares, new issues for the quarter ending 2025-09-30 was 0.00 shares.
- Seres Therapeutics, Inc. stock issued during period, shares, new issues for the quarter ending 2025-06-30 was 0.00 shares.
- Seres Therapeutics, Inc. stock issued during period, shares, new issues for the quarter ending 2025-03-31 was 714.28K shares.
- Seres Therapeutics, Inc. stock issued during period, shares, new issues for fiscal 2025 was 714.28K shares, a 95.00% decline from fiscal 2024.
- Seres Therapeutics, Inc. stock issued during period, shares, new issues for fiscal 2024 was 14.29M shares.
| Period end | Stock Issued During Period, Shares, New Issues 3 month | Stock Issued During Period, Shares, New Issues 12 month |
|---|---|---|
| 2025-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | 714.28K shares 10-K · filed 2026-03-12 |
| 2025-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | 14.29M shares derived: sum of 4 quarters · filed 2025-11-05 |
| 2025-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | 714.28K shares derived: sum of 4 quarters · filed 2026-03-12 |
| 2025-03-31 | 714.28K shares 10-Q · filed 2025-05-07 | |
| 2024-12-31 | 13.57M shares derived: 10-K 12 month − 10-K 9 month · filed 2025-03-13 | 14.29M shares 10-K · filed 2025-03-13 |
| 2024-09-30 | -13.57M shares derived: 10-K 9 month − 10-Q 6 month · filed 2026-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| ROCKWELL MEDICAL, INC. (RMTI) | United States | $0.035B | |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Context Therapeutics Inc. (CNTX) | United States | $0.034B | -1.10 |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B |